BACKGROUND: Gout is a metabolic disorder characterized by the accumulation of urate crystals in joints due to a high concentration of uric acid in the blood. This leads to inflammation and joint swelling. Gout is traditionally treated with drugs that lower the uric acid level and reduce inflammation, but these treatments can have adverse effects. Phytopharmaceuticals, such as cinnamaldehyde nanoparticles (CANPs), have gained popularity as gout treatments. The study aimed to explore the anti-gout and antioxidant activities of CANPs in gouty mice. METHODOLOGY: Cinnamon bark was used to synthesize CANPs, which were then characterized. The in vivo study was conducted using BALB/c mice, randomly divided into six groups (n = 6 per group). The control group received a normal diet, while the MSU group was injected with monosodium urate (MSU) crystals into the ankle joint to induce a disease model. The allopurinol group was treated with the standard drug allopurinol, serving as a positive control. Three treatment groups were administered different doses of CANPs
the experimental drug at concentrations of 5 ppm, 10 ppm, and 20 ppm, respectively. CANPs were subsequently administered orally to the mice. CANPs were studied for their impact on liver function, renal function, lipid profile, total protein, antioxidant activity, and blood parameters. RESULTS: CANP administration had a favorable effect on gouty mice, according to the findings. CANPs dramatically lowered uric acid, urea, and creatinine concentrations, demonstrating their potential for treating hyperuricemia and gout. CANPs improved liver function, lipid profile, antioxidant activity, and blood parameters. CONCLUSION: The study suggests that CANPs derived from cinnamon exhibit anti-gout and antioxidant properties in gouty mice. These findings support the potential use of CANPs as a natural and alternative treatment for gout. Further research is needed to explore the therapeutic applications of CANPs in treating gout in humans.